Get started
Live feed
·
PRReleasevia Quantisnow
Actinium Pharmaceuticals Inc. (Delaware) logo

Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023

ByQuantisnow·Wall Street's wire, on your screen.
ATNMActinium Pharmaceuticals Inc. (Delaware)
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATNM (Actinium Pharmaceuticals Inc. (Delaware)) and more on Quantisnow.